The safety and efficacy of prolonged infusion of alphaxalonelalphadolone (Aljathesin: Glaxo) was assessed in 20 critically ill patients needing sedation during intermittent positive pressure ventilation in a general intensive care unit. The mean dose of Aljathesin infused was 1542 ml (range: 225 to 4820 ml) over 6.9 days (3 to 16 days) at rates between 5 and 15 mllhour. Significant increases in plasma urea, creatinine, bilirubin, alkaline phosphatase and white cell count occurred during the infusion, but these were expected from each patient's clinical course. Lipoprotein electrophoresis invariably showed loss of the alpha band and appearance of a densely staining prebeta band. Four patients had involuntary movements during the infusion and two patients fitted when the infusion stopped. Both had cerebral injuries. Subjective assessment of the quality of sedation was "very good" or "good" in 15 patients and "fair" in five.
Many patients admitted to intensive care units need sedation during prolonged intermittent positive pressure ventilation. A number of different drug regimens have been used, I but none is entirely satisfactory.
Alphaxalone/alphadolone (Alfathesin) was introduced as an anaesthetic induction agent and more recently has been given as a continuous infusion for maintenance of anaesthesia. 2 More prolonged infusions are now being used for sedation,l control of status epilepticus,4.5 and for control of intracranial pressure. 6 However, except for a study by Ramsay et al., J there is little information about its safety and efficacy when given for prolonged periods. This study was designed to assess these factors in critically ill patients needing intensive care.
METHODS
Twenty patients who needed controlled ventilation were studied during a 12 month period. The study design was approved by the Human Rights Committee of the Royal Perth Hospital. Informed consent for participation in this study was obtained from the next of kin. The patients had all been difficult to sedate with combinations of diazepam, droperidol, and narcotic analgesics, as shown by obvious patient distress or difficulties in maintaining intravascular cannulae and endotracheal and nasogastric tubes. Patients were excluded if they were pregnant, had hepatic failure, a history of allergic response to Alfathesin or Cremophor, or a history of asthma or epilepsy.
The Alfathesin was transferred from 5 ml ampoules into bags of 250-300 ml by the pharmacy under sterile conditions under a laminar flow hood. The standard preparation was infused through a central venous catheter and the infusion rate controlled by a constant infusion pump. If necessary, an initial bolus dose of the drug, sufficient to put the patient to sleep (2-5 ml) was given over 3-5 minutes in severely agitated or restless patients. The infusion rate was then adjusted between 5 and 15 mllhour to give the minimum dose for satisfactory sedation. Further adjustments to the infusion rate were made as necessary during the infusion to maintain this level of sedation. The volume infused each day was recorded as well as the infusion rates. All patients had continuous electrocardiographic monitoring and at least hourly recordings of blood pressure, central venous pressure, tidal volume and minute volume.
Plasma concentrations of sodium, potassium, bicarbonate, glucose, urea and creatinine were measured daily and plasma concentrations of protein, albumin, calcium, phosphate, uric acid, bilirubin and alkaline phosphatase on alternate days. A full blood count was obtained at least second daily. Lipoprotein electrophoresis and plasma cholesterol and triglyceride concentrations were measured before treatment, after three days and after the infusion was stopped.
Whenever possible an electroencephalogram was obtained before starting an infusion and after 48 hours of treatment.
Patients were observed closely for the development of involuntary movements, epileptiform activity, anaphylactic or allergic responses and other possible side effects.
If there were no contraindications the Alfathesin infusion was stopped every two to three days in order to record the time taken for recovery of consciousness. This was recorded as the time between the infusion being stopped and the patient opening his eyes on command. If required, the infusion was then restarted.
Any sedatives, analgesics or muscle relaxants given during the infusion were recorded. A subjective evaluation of the overall quality of sedation achieved was made by the physician in charge of the patient. Efficacy was recorded as "very good", "good", "fair" or "unsatisfactory" . Twenty patients were studied. Details of age, sex, diagnosis, volume of Alfathesin infused and duration of the infusion are shown in Table  1 . The mean total dose of Alfathesin was 1,542 ml given over an average of 6.9 days at infusion rates varying from 5 to 15 mllhour.
The results of biochemical and haematological investigations at the beginning and end of the infusion are recorded in Table 2 . Although there were statistically significant increases in urea, creatinine, bilirubin and alkaline phosphatase (p < 0.01, paired Student's t test) these would have been predicted from the clinical course of the patients, many of whom were critically ill when infusion was started and subsequently developed multiple organ failure. The leukocytosis and reactive thrombocytosis can be explained similarly. There were no cases of unexpected renal or hepatic failure in this series of patients.
Lipoprotein, cholesterol and triglycerides
All patients in whom lipoprotein electrophoresis was performed during the infusion (15 patients) developed an abnormal lipoprotein pattern with no alpha band and an abnormally fast densely staining beta and prebeta band (Figure 1 electrophoresis performed the day after stopping the infusion still showed this abnormality. In two patients lipoprotein electrophoresis was performed 4 and 5 days after the infusion was stopped. By this time the lipoprotein pattern had returned to normal except for the continuing absence of an alpha band. Triglyceride levels rose significantly (p < 0.001, paired Student's t test) during the infusion (Table 3) . Electroencephalography Electroencephalographs were recorded from 11 of the 20 patients before starting and also during the infusion of Alfathesin. In all eleven patients the electroencephalograms before the infusion were abnormal with most showing bilateral slow wave activity. During the infusion the electroencephalograms were again diffusely abnormal, usually with delta and theta background activity. Only two patients exhibited burst suppression.
Fitting; involuntary movements
Four patients had twitching movements, usually of the upper limbs and face, which may have been due to the Alfathesin. Two patients began fitting when the infusion was stopped and subsequently required clonazepam to control the fits. In one patient the cause of the fits was thought to be hypoxic encephalopathy and the other to be metabolic encephalopathy and/or head injury. One patient with multiple injuries, including a head injury, developed grand mal epilepsy on the fourteenth day of treatment. A thiopentone infusion was therefore substituted for the Alfathesin. Another patient was discovered to have a past history of epilepsy after being included in the study and the infusion was therefore stopped on the fourth day.
Allergic and adverse reactions
No anaphylactic or allergic reactions in the form of bronchospasm or skin rashes were noted.
Two patients developed clinical evidence of axillary vein thrombosis on the side into which the drug was being infused through an infraclavicular central venous catheter. In both patients, however, the same route had been used for other central venous catheters and for infusion of other fluids and drugs.
Recovery time
Recovery time averaged 56 minutes with a median of 23 minutes (range 15-240 minutes). No evidence of delayed recovery time after a prolonged period of infusion was found.
Recovery time could not be tested satisfactorily in 10 of the patients because of underlying cerebral pathology (e.g. hypoxic encephalopathy, head injury).
Other drugs and evaluation of sedation
Three patients received no sedative drugs other than Alfathesin during the infusion. Good or very good sedation was achieved in these patients. The other 17 patients received occasional supplemental sedation or analgesia with diazepam, phenoperidine or papaveretum. The indications for analgesia were the usual signs of pain in an anaesthetised patient including sweating, lacrimation, tachycardia or hypertension when other causes were excluded. These drugs were discontinued well before any assessment of recovery time from Alfathesin was made.
Evaluation of sedation as assessed by the physician in charge is recorded in Table 4 . This study has confirmed that Alfathesin provides satisfactory sedation for intensive care patients on ventilators. In all cases it was possible to relieve obvious patient distress and enable the patient to tolerate the tubes and catheters required for optimum patient management and so facilitate nursing care. The major advantages of Alfathesin are that it can be given as a continuous infusion of relatively small fluid volumes, the recovery time is rapid, intracranial pressure is reduced and fitting may be controlled.
Continuous infusion of the preparation results in a fairly constant level of sedation and avoids the need for frequent doses of other sedative drugs. The level of sedation can easily be adjusted as the patient's condition changes. The relatively small volume (5-15 mllhour) needed is a major advantage compared, for example, with chlormethiazole for which doses of 50-200 mllhour are usually required. 7 Recovery time was rapid even after two weeks of treatment, a considerable advantage over many other sedative or hypnotic drugs used in intensive care. It is especially useful in patients with encephalopathy or head injury in that it allows neurological assessment of the patient within a short time of stopping the infusion.
Several studies have shown that alphaxalone/alphadolone reduces intracranial pressure together with cerebral blood flow and cerebral oxygen consumption. 6 . 8 This may be an advantage in the management of patients with head injury or hypoxic encephalopathy.
Alphaxalone/alphadolone infusions have been used successfully to control status epilepticus. 4 ,s In this study two of the patients had grand mal convulsions when the infusion was stopped, suggesting that Alfathesin was controlling the fits until that time. While the possibility of the fits being a withdrawal phenomenon after a prolonged infusion of the drug cannot be excluded, both patients had underlying intracranial injuries from which fitting is a common complication. Alphaxalone/alphadolone has been reported to cause convulsions in rare instances 9 -12 and for this reason the Commonwealth Department of Health required patients with a history of epilepsy to be excluded from this study. At present the place of alphaxalone/alphadolone in the treatment of epilepsy is uncertain.
The disadvantages of alphaxalone/alphadolone infusions are its cost and equipment requirements, the delayed excretion of the solvent and the possibility of side effects.
The cost of the drug, filters and infusion bag has been calculated by the pharmacy to be approximately $65 a day for a 250 ml bag. This excludes the labour costs which are significant when the drug is supplied only in 5 ml ampoules. In addition, the cost of an infusion pump and the need for another intravenous catheter must be considered. An infusion pump may be unnecessary if the preparation is diluted to a larger volume of aqueous solution, but the volume infused may then be a problem in patients in need of fluid restriction.
The abnormality of lipoprotein electrophoresis associated with Alfathesin infusions has been shown in this and other studies l3 -ls to be due to the solvent Cremophor E.L., which is polyoxyethylated castor oil. The preparation we used contained 20070 Cremophor E.L. as a solvent. No harmful Anaesthesia and intensive Care, Vol. 11, No. 2, May, 1983 effects have been demonstrated from Cremophor E.L. in the short term. However, a study has been undertaken in rats given polyoxyethylated castor oil intra peritoneally daily for 50 days. IS Examination of the thoracic aortas of the rats after 50 days showed striking amorphous myxomatous separation of elastic fibres of the media and focal areas of calcification. In view of these arterial wall changes in rats it would appear prudent to limit the duration of infusion in humans to 1-2 weeks.
Side effects in this study were limited to spontaneous muscle movement and possibly venous thrombosis. The involuntary movements have been noted in previous studies and are fairly common. 16 It is not possible to determine whether the venous thrombosis occurring in two of the patients in this study was related to the Alfathesin infusion or other central venous catheters or drug infusions. It was the aim of this study to report all adverse events occurring during Alfathesin infusion. There are no reported cases of venous thrombosis caused by Alfathesin infusions, but neither are there any previous reports of undiluted Alfathesin being infused for prolonged periods. The incidence of clinically evident venous thrombosis associated with subclavian vein cannulation and Alfathesin infusion in this series (2 in 138 catheter days in 20 patients) compares with 8 in 1770 catheter days in 77 patients with subclavian cannulae for parenternal nutrition l7 and a total of 5 in 3291 catheter days in 104 patients with central venous catheters used for parenternal nutrition in another series. 18 Acute renal failure has been reported to the Australian Drug Evaluation Committee in patients with severe intracranial hypertension from head trauma who received Alfathesin, mannitol and frusemide. Dehydration may have been an important contributory cause and infusion rates used exceeded those allowed in the protocol for this study. No cases of unexpected renal failure were seen in patients in this study and none have been subsequently in patients treated according to the same protocol.
In conclusion, this study has confirmed the results of Ramsay et al. 2 that alphaxalone/alphadolone as an infusion is safe and effective for sedation of intensive care patients. In addition, the effect of this agent on lipoprotein electrophoretic pattern and its delayed return to normal have been demonstrated. The only possible new side effect noted was axillary vein thrombosis which could be due to administration of the drug via a central line in its undiluted form. In order to be more certain about the absence of side effects a large controlled study would be required. This would be difficult to conduct in view of the small number of patients requiring this therapy and their wide range of pathology.
